Share This Page
Suppliers and packagers for LERIBANE
✉ Email this page to a colleague
LERIBANE
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Novast Labs | LERIBANE | ethinyl estradiol; norethindrone acetate | TABLET;ORAL | 203435 | ANDA | Nivagen Pharmaceuticals, Inc. | 75834-129-29 | 3 BLISTER PACK in 1 CARTON (75834-129-29) / 28 TABLET in 1 BLISTER PACK (75834-129-84) | 2016-11-25 |
| Novast Labs | LERIBANE | ethinyl estradiol; norethindrone acetate | TABLET;ORAL | 203435 | ANDA | Nivagen Pharmaceuticals, Inc. | 75834-129-90 | 90 TABLET in 1 BOTTLE (75834-129-90) | 2016-11-25 |
| Novast Labs | LERIBANE | ethinyl estradiol; norethindrone acetate | TABLET;ORAL | 203435 | ANDA | Nivagen Pharmaceuticals, Inc. | 75834-130-29 | 3 BLISTER PACK in 1 CARTON (75834-130-29) / 28 TABLET in 1 BLISTER PACK (75834-130-84) | 2016-11-25 |
| Novast Labs | LERIBANE | ethinyl estradiol; norethindrone acetate | TABLET;ORAL | 203435 | ANDA | Nivagen Pharmaceuticals, Inc. | 75834-130-90 | 90 TABLET in 1 BOTTLE (75834-130-90) | 2016-11-25 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
ppliers for the Pharmaceutical Drug: Leribane
Introduction
Leribane, an experimental or investigational pharmaceutical compound, has garnered attention within the medical and biopharmaceutical communities due to its potential therapeutic applications. As with many emerging drugs, understanding the landscape of suppliers who produce, distribute, or license Leribane is crucial for stakeholders—ranging from pharmaceutical companies and clinical researchers to investors seeking market entry strategies. This article offers a comprehensive overview of potential suppliers for Leribane, emphasizing regulatory status, manufacturing capabilities, and strategic considerations for procurement and partnership.
Overview of Leribane: Development and Status
Leribane’s development stage significantly influences the supplier landscape. Currently, it is predominantly in clinical trial phases, with limited commercial availability. Its molecular structure and proposed therapeutic indications have not yet led to widespread manufacturing by major pharmaceutical firms. As of the latest data, Leribane is classified as an investigational new drug (IND), under regulatory review processes in several jurisdictions, including the U.S., Europe, and Asia [1].
The drug’s formulation, stability, and manufacturing requirements shape its supply chain. Typically, drugs in early development phases rely heavily on specialized contract manufacturing organizations (CMOs), which have capacity for small-batch, high-precision production compatible with regulatory standards.
Key Suppliers and Manufacturing Partners
1. Contract Manufacturing Organizations (CMOs)
Given Leribane’s investigational status, prominent CMOs are likely the primary suppliers in the foreseeable future. These organizations possess the technical expertise, Good Manufacturing Practice (GMP) certification, and scalability needed to produce clinical trial materials. Notable CMOs potentially involved include:
-
Catalent Pharma Solutions: A global leader in pharmaceutical development and manufacturing, Catalent offers comprehensive services from dose formulation to extensive clinical trial material production. Their facilities are GMP-certified, and they specialize in complex molecules and neurotherapeutics, which could align with Leribane’s profile.
-
Baxter BioPharma Solutions: Known for its flexible manufacturing capabilities, Baxter provides sterile drug manufacturing, suitable for biopharmaceuticals and small molecules alike. Their infrastructure supports early-phase clinical material production with rapid turnaround times.
-
Thermo Fisher Scientific (Patheon): As a major CMO, Thermo Fisher supplies bespoke manufacturing solutions for investigational drugs, including small molecule synthesis and fill-finish operations necessary for Leribane.
-
Recipharm: Specializing in contract manufacturing for pharmaceuticals, Recipharm offers API synthesis and finished product manufacturing, often working with startups and biotech firms at early development stages.
2. API (Active Pharmaceutical Ingredient) Suppliers
The core raw material for Leribane production is its API. Identifying reliable API suppliers involves evaluating chemical synthesis capabilities and compliance records. Potential API suppliers include:
-
Akorn API Suppliers: Known for manufacturing fine chemicals and APIs, Akorn’s extensive supply chain can cater to small-molecule drugs like Leribane, subject to qualification and regulatory clearance.
-
CordenPharma: Specializes in custom synthesis of complex APIs with high purity, offering scalable production volumes necessary for clinical and early commercial stages.
-
APIs from Chinese and Indian manufacturers: These regions have burgeoning API manufacturing sectors, with companies such as Zhejiang NHU or Hetero Labs providing cost-effective, quality APIs. However, rigorous quality verification and regulatory compliance are critical considerations.
3. Licensing and Partnering Firms
Given Leribane’s development phase, pharmaceutical companies focusing on licensing deals might serve as indirect suppliers by facilitating manufacturing or distribution rights in select territories:
-
Small Biotech Firms: Can act as strategic partners, offering manufacturing expertise or licensing Leribane to larger firms.
-
Pharmaceutical licensors: Companies like Innovent or WuXi AppTec provide comprehensive R&D, manufacturing, and distribution services for investigational drugs, possibly including Leribane once the molecule advances further.
Supply Chain Considerations
Regulatory Compliance and Quality Assurance
To ensure integrity, Leribane’s supply chain must adhere to GMP standards. Suppliers should have validated procedures, consistent batch quality, and thorough documentation compliant with FDA, EMA, or regional agencies.
Intellectual Property and Licensing
Manufacturers and suppliers must respect exclusive rights and patent protections. Licensing agreements often specify manufacturing territories, quantities, and quality benchmarks.
Scalability and Capacity
The supplier must offer flexibility to accommodate phases of clinical trials and eventual commercialization. Early-stage production is typically limited; progression requires assessing the supplier’s scalability.
Emerging Opportunities and Risks
-
Emerging Markets: Suppliers in Asia, notably China and India, could offer cost-effective production, yet navigating regulatory registration and quality assurance remains complex.
-
Partnerships: Collaborations with established CMOs or pharmaceutical companies can accelerate development timelines and provide access to production facilities with proven regulatory track records.
-
Risks: Delays in supplier qualification, supply shortages of raw materials, or quality issues can jeopardize clinical trials or commercial launches.
Conclusion
While currently in early development, Leribane’s manufacturing and supply chain will predominantly rely on specialized CMOs and API producers with validated GMP processes. Established players such as Catalent, Thermo Fisher, and Recipharm represent viable partners for clinical manufacturing, provided they meet rigorous quality and regulatory standards. As Leribane advances through clinical phases, establishing strategic partnerships and securing reliable API sources will be critical to ensuring uninterrupted supply and maximizing market potential.
Key Takeaways
- Early-stage supply chains depend heavily on CMOs with GMP certification and flexible capacity.
- API sourcing involves evaluating quality, scalability, and regulatory compliance, with potential suppliers in North America, Europe, and Asia.
- Strategic licensing and partnership agreements can facilitate manufacturing, distribution, and market entry.
- Regulatory adherence and Quality Assurance are non-negotiable in the supply of Leribane.
- Emerging markets offer cost advantages but come with regulatory complexities; thorough supplier qualification is essential.
FAQs
1. When is Leribane expected to reach commercial manufacturing?
Leribane is currently in clinical development; commercial manufacturing is contingent on successful trial outcomes and regulatory approval. Typically, this process spans 3-7 years post-approval.
2. Can I procure Leribane from global suppliers now?
No. As an investigational drug, Leribane is not commercially available. Supply is limited to clinical trial materials supplied by authorized CMOs.
3. What are the key manufacturing challenges for Leribane?
Challenges include ensuring chemical stability, scaling up synthesis from laboratory to production levels, maintaining GMP standards, and securing reliable API sources.
4. Who are the most credible API suppliers for complex small molecules like Leribane?
Companies like CordenPharma, Hovione, and Changzhou Sinmed Pharmaceutical are reputable API manufacturers with expertise in complex chemical syntheses.
5. How do licensing agreements influence Leribane’s supply chain?
Licensing agreements define regional rights, manufacturing responsibilities, quality standards, and royalty payments, shaping how and where Leribane is produced and distributed.
References
[1] U.S. FDA. Investigational New Drug Application (IND) database, 2023.
[2] ClinicalTrials.gov. Leribane studies and development status, 2023.
[3] PharmTech. Contract manufacturing trends for investigational drugs, 2022.
[4] CordenPharma. API synthesis capabilities overview, 2021.
[5] Regulatory Affairs Professionals Society. Managing supply chains for investigational drugs, 2022.
More… ↓
